Providing Transgender Inclusive Healthcare

Ryan Nall MD Associate Professor of Medicine Division of General Internal Medicine University of Florida College of Medicine



Learning Objectives

- 1. Describe health disparities faced by transgender people
- 2. List 5 ways you can make your practice more inclusive to transgender patients
- 3. Understand when to initiate gender affirming hormone therapy
- Describe special considerations for HIV prevention and care for transgender people
- 5. Recall online trans health resources




No disclosures

This program is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) under grant number U10HA30535. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government. For more information, please visit HRSA.gov.




Meet Jolene

Jolene is a 25 yo transgender woman who you meet at a local Pride event where you have a booth with information on your local clinic which offers PrEP clinic. She shows great interest however has concerns about setting up an appointment at the clinic.



I've had some really bad experiences at the doctor.... I'm pretty nervous to come.



Southeast

Transgender: Gender identity opposite as assigned at birth

Cisgender: Gender identity same as assigned at birth

Gender Non-Binary/Gender Queer: Gender identity not male or female


Why is providing transgender inclusive healthcare important?



You will care for transgender patients!

- 1º source: The Williams Institute, UCLA
 - June, 2016, report: used CDC Behavioral Risk Factor Surveillance System
- 1.4 M adults (0.6% U.S. population)

Figure 1. Estimated Percentage of the Population by Race and Ethnicity for the Adult General Population and Trangender-Identified Adults



Prevalence of Type 1 DM in USA: 0.55% or 1.3M



Flores, A. R, et al. The Williams Institute. October, 2016 pp.1-15.



What is the estimated HIV infection prevalence among trans women?

A. 14%
B. 44%
C. 26%
D. 7%



- 81% report workplace harassment or mistreatment
- 78% report harassment, 41% reported physical assault at school
- 40 % reported attempting suicide at some point in their life
- Transwomen HIV prevalence 14%, Black Transwomen 44%

National Transgender Discrimination Study, 2015

Herbst JH, Jacobs ED, Finlayson TJ, et al. Estimating HIV prevalence and risk behaviors of transgender persons in the United States: A systematic review. AIDS Behav. 2008;(12):1-17.



- 55% of those who sought coverage for transition-related surgery in the past year were denied
- 25% of those who sought coverage for hormones in the past year were denied
- 33% of those who saw a health care provider in the past year reported having at least one negative experience
- 23% of respondents did not see a doctor when they needed to because of fear of being mistreated

National Transgender Discrimination Study, 2015





STATES WITH TRANSGENDER COVERAGE EXCLUSIONS IN MEDICAID

STATES WITH BANS ON INSURANCE EXCLUSIONS FOR TRANSGENDER HEALTHCARE



Words matter!



Pronouns > Patient Centered Care

- Don't make words your barrier to providing Transgender care
- Be patient centered and ASK or Collect at Check In
 - What name do you prefer?
 - What pronouns do you prefer?
- To err is human....it is okay if you mess up, just apologize and get it right the next time




Examples

- "What pronouns do you use?"
- "How would you like me to refer to you?"
- "How would you like to be addressed?"
- "Can you remind me which pronouns you like for yourself?"
- "My name is Dr. Nall and my pronouns are he, him, and his. What about you?"

- 1. What is your current gender identity? (Check an/or circle ALL that apply)
 - Male
 - Female
 - Transgender Male/Trans Man/FTM
 - Transgender Female/Trans Woman/MTF
 - Genderqueer
 - Additional category (please specify):
 - Decline to answer
- 2. What sex were you assigned at birth? (Check one)
 - □ Male
 - Female
 - Decline to answer
- 3. What pronouns do you prefer (e.g., he/ him, she/her)?

Improving the Health of LGBT People, Fenway Institute

SOGI: Sexual Orientation and Gender Identity in EPIC



5 ways to make your practice more inclusive of transgender patients





#1 - It Starts at the Front Door!

- Inclusive language on website
- Training for ALL staff
- Welcoming waiting room, provides privacy
- Chairs facing away from door, trees/plants, TV
- Openly display non-discrimination statement



We welcome: All races All religions All countries of origin All sexual orientations All genders All ethnicities All abilities

We stand with you.

UCsF Health








#2 – Do patients see themselves in your clinic?

- Inclusive brochures/signage
- Inclusive intake forms
- Pictures on walls
- Diverse staff



Cancer Facts for Lesbians and Bisexual Women

Share this with someone you care about.





Do Ask, Do Tell





Let your provider know if a you are LGBT. Your provider will welcome the conversation. Start today!

Aufordation (Aufordation)
 Aufordation
 Aufordation



Signal you are safe







#3- Reduce Stigma (WALLS)

- Watch your language: avoid stigmatizing language/actions
- Ask questions: learn from LGBTQ+ patients
- Learn more: reduce misunderstandings
- Listen to experiences: listen to patients' experiences
- Speak out: speak out when others stigmatize






Image:https://providecare.org/how-identify-signs-symptoms-individual-stigma/




LGBTQ Services at the Equal Access Clinic Network



of student-run free health care services that provide care to uninsured and underinsured patients in Gainesville, Florida. What we offer: Specially-trained providers No-cost visits

Pap smears

Third Tuesday of each month, 5 – 9 p.m. UF Health Family Medicine – Eastside 410 NE Waldo Road





Department of Community Health and Family Medicine UNIVERSITY of FLORIDA

352.273.9425 | equalaccess.med.ufl.edu | eacn@med.ufl.edu



#4 – Community Outreach




#5 - Provide Gender Affirming Care

- Social/Emotional Affirmation
 - Name and pronouns
 - Dress, Binding, Tucking, Packing, Padding
 - Coming out
- Medical affirmation
 - Hormones
 - Hair removal
 - Voice Therapy
 - Surgery
- Legal affirmation
 - Identity documents

"I would like to offer a new lens, one that casts gender non-conformity in a positive light, in order not to squelch it but facilitate it"

-Diane Ehrensaft PhD





Equal Access Gender Affirming Therapy: Masculinizing (FtM)

LGBT Health Clinic Developed by Catherine Bieldx, 2017-2018OinicDiredor, updated 2021 by Monica Rodriguez, LGBT Officer

Begin HRT afte

discussion of

risks and

benefits



Patient obtains baseline labs

Initial Evaluation

started

Baseline history and counseling

at Eastside

Initial

evaluation in

clinic

- Mood status (PHQ-9, GAD6, Mood Disorder Questionnaire)
- Suicidal ideation
- Smoking status & other VTE/hypercoagulable risk factors
- Desire for fertility counsel on fertility options
- Set expectations for what changes to expect from GAT (reference)
 - Skin oiliness; 1-6 months; 1-2 years
 - Facial/body hair growth; 3-6 months; 3-5 years
 - Scalp hair loss; >12 months; variable
 - Increased muscle mass/strength; 6-12 months; 2-5 years
 - Body fat redistribution; 3-6 months; 2-5 years
 - Cessation of menses; 2-6 months; n/a
 - Clitoral enlargement; 3-6 months; 1-2 years
 - Vaginal atrophy; 3-6 months; 1-2 years
 - Deepened voice 3-12 months; 1-2 years
- Absolute Contraindications: any active testosterone-sensitive cancer
- Complete Informed Consent Form & Upload to patient chart
- Enroll patient in Gender Affirming Therapy in the Clinic Navigator

Labs Baseline & Prior to Every Visit

- CBC without diff (Hg and Hct for erythropoietic effect)
- CMP
- Serum Estradiol (not total estradiol)
- Serum Total Testosterone LC/MS/MS
- Pregnancy Test (always at baseline, follow up if pregnancy is possible)
- No evidence to support extra monitoring, lipids, AIC/ducose, cholesterol



Reevaluation at

with labs prior)

Therapeutic Options

Reevaluation at

12 months

(with labs prior)

Testosterone Cypionate IM or SQ:

Initial 50 mg/wk; Max 100 mg/wk

•Can double each dose for q 2-week dosing Others (for reference)

 Testosterone Enthanate IM or SQ: Initial 50 mg/wk; Max 100 mg/wk

Reevaluation at

6 months

(with labs prior)

- Testosterone topical gel 1%: Initial 50 mg qAM; Max 100 mg qAM
- Testosterone topical gel 1.62%: 40.5-60.75mg qAM; Max 103.25mg qAM
- Testosterone Patch: Initial 4 mg gPM; Max 8 mg qPM
- Testosterone cream: initial 50 mg, Max 100 mg
- Testosterone Axillary gel 2%: Initial 60 mg qAM; Max 90-120 mg gAM
- Testosterone Udecanoate: Initial 750 IM repeat in 4 weeks, q 10 weeks

Testosterone Treatment Risks

Erythrocytosis/polycythemia

•Use reference male range

- Management of polycythemia
- 1)Check testosterone levels, including peak levels adjust dose
- 2)More frequent injection schedule with lower peak dose may lower risk [59]
- 3) Phlebotomy or blood donation short term solution
- 4)Rule out pathologic causes of polycythemia

(OSA, tobacco, etc)

Hair Loss

 Fronto-temporal pattern, severity based on genetics

Management

- OTC Minoxidil (Rogaine)
- 5-alpha reductase inhibitors (finasteride/dutasteride)
- Surgical approaches scalp advancement, hair transplantation

Acne

- · Peaks in first year of testosterone therapy then declines
- Treat as normal with topical skin treatments escalating with severity

Weight gain

· Must use with caution and informed consent with PCOS, obese, or hyperlipidemic patients

Health Maintenance

- Pap smears: follow USPSTF, likely behind, based on age
- Can be traumatizing "checkitoutguys.ca" is good patient resources for FTM's
- MUCH higher rate of inadequate cytologic sampling (possibly due to rushing procedure from patient discomfort)[31]
- Can pre-medicate with vaginal estrogens 1-2 weeks prior to exam to decrease vaginal atrophy due to testosterone therapy
- If still refuses offer external OR bimanual as initial step towards establishing trust

Goals

Titrate GAT dosing to the physiologic range of nontransgender individual of identified gender

(levels vary by lab – Quest lab ranges listed)

Physiologic range of non-transgender males ≥18yo

- Total Testosterone = 400-700 ng/dL (test code 15983)
- Serum Estradiol = can vary greatly not great priority
 - Only 29% of 31 trans men achieved physiologic male-range estradiol levels

Gender Affirming Therapy: Feminizing (MtF)

Developed by Catherine Bieldk, 2017-2018 Cinic Director, updated 2021 by Monica Rodriguez, LGBT Officer

risks and

benefits



Initial Evaluation 0

Baseline history and counseling

Equal Access

LGBT Health Clinic

at Eastside

Initial

evaluation in

clinic

- Mood status (PHQ-9, GAD6, Mood Disorder Questionnaire)
- Suicidal ideation
- Smoking status & other VTE/hypercoagulable risk factors
- Desire for fertility counsel on fertility options

Informed

started

- Set expectations for what changes to expect from GAT (reference)
 - Body fat redistribution; 3-6 months; 2-5 years
 - Decreased muscle mass/strength; 3-6 months; 1-2 years
 - Softening of skin/decreased oiliness; 3-6 months; unknown
 - Decreased libido; 1-3 months; 3-6 months
 - Decreased spontaneous erections: 1-3 months: 3-6 months
 - Male sexual dysfunction; variable; variable
 - Breast Growth; 3-6 months; 2-3 years
 - Decreased testicular volume; 3-6 months; 2-3 years
 - Decreased sperm production; variable; variable
 - Thinning and slowed growth of body and facial hair; 6-12 months; >3 vears
 - Male pattern baldness; no regrowth, loss tops 1-3 months; 1-2 vears
- Absolute Contraindications: any active estrogen-sensitive cancer
- Complete Informed Consent Form & Upload to patient chart
- Enroll patient in Gender Affirming Therapy in the Clinic Navigator

Labs Baseline & Prior to Every Visit

- Serum Estradiol (NOT TOTAL estradiol)
- Serum TOTAL testosterone LC/MS/MS
- (free testosterone is unreliable [33])
- CMP

Therapeutic Options

Reevaluation at

3 months

(with labs prior)

Estrogen – administer FIRST^[36]

Bioidentical Estradiol Oral/Sublingual (most typical)

Reevaluation at

6 months

(with labs prior)

12 months

(with labs prior)

- Initial: 2-4 mg/day
- Maximum: 8 mg/day (BID dosing if >2 mg daily)

Others:

- Estradiol Transdermal (lower or absent clotting risk [35])
- Initial 100 mcg per [timing brand/product-dependent]
- Maximum 100-400 mcg per timing brand/product
- Estradiol valerate IM: Initial 20 mg IM g 2wk; Max 40mg IM q 2wk
- Estradiol cypionate IM: Initial 2 mg IM g 2wk; Max 5 mg IM a 2 wk
- Note: Conjugated equine estrogens (Premarin) are no longer recommended due to high risk of thrombogenicity and cardiovascular risk [38,39]

Androgen Blocker – Administer SECOND [32,36] – Spironolactone: Initial: 50 mg BID,Max: 200 mg BID **Optional Adjuncts (for reference)**

- Finasteride 1-5 mg/day depending on desired effect
- Dutasteride 0.5 mg/day
- Progestagen
 - Micronized progesterone 100-200 mg/night
 - Medroxyprogesterone acetate (Provera), less preferred
 - Initial 2.5 mg/night: Max 10 mg/night

Goals: Titrate GAT dosing to the physiologic range of nontransgender individual of identified gender

(levels vary by lab - Quest lab ranges listed)

- Physiologic range of mid-cycle non-transgender female
 - Estradiol = 64-357 pg/mL (test code 4021 can google to order)
 - Total Testosterone = 2-45 ng/dL (test code 15983)

No evidence to support extra monitoring: lipids, A1c/glucose, cholesterol

Estrogen Treatment Risks

Venous Thromboembolism

- VTE background rate in general pop: (1/1,000-1/10,000)
- Data on risk of oral 17-Beta estradiol (bioidentical) is MIXED - Some = no increased risk [49]
 - Some = 2.5-4 fold increase in relative risk (still low absolute risk)^[50,51]
- Often quoted study: [52,53] Found 20-40-fold times risk of VTE in transgender women, BUT:
 - 1) high doses (100-200 mcg/day)
 - 2) thrombogenic ethinyl estradiol(conjugated) used and
 - 3) Mix of smokers and non-smokers in cohort
- Routine hypercoagulability screening is not recommended
- Withhold estrogen therapy when: 1) patients with significant risk factors/history of VTE and 2) who continue to smoke tobacco
- If risks are great, but manageable—consider transdermal estrogen application

Loss of erectile function

- Some do not lose, can be safely preserved with Viagra or Cialis Libido loss
- 22% met criteria for Hypoactive Sexual Desire Disorder (HSDD), no correlation with testosterone levels [59]
- Mental health therapy continue throughout treatment to help with body image issues and dissociative symptoms

Prolactinoma^[56]

- Few case reports reporting association with estrogen therapy Prolactin levels should only be checked in cases
 - ofVisual disturbance. Excessive galactorrhea. New onset headaches

Migraine

- Estrogen known association with menstrual migraines (by period cycle in non-transgender women)
- May be exacerbated with feminizing GAT

Infertility

Sperm cryopreservation may be required

Other Health Concerns

- **Prostate Exams:** follow current guidelines, prostatic atrophy may be severe if on finasteride
- Hernias: If pre-operative SRS MUST monitor tucking genitals can cause hernias or perineal skin breakdown
- If post-operative SRS and needs vaginal exam NO cervix or fornices – pap smears unnecessary (/impossible)
- Visualization of tissue may be better with an anoscope (if necessary, EAC would need WeCare referral)




Jolene asks if she can take PrEP if she is on gender affirming hormones (estradiol). How would you respond?

- A. No, hormones lower FTC/TDF drug levels
- B. No, FTC/TDF lowers testosterone and estrogen levels
- C. Yes, but you need to double the dose
- D. Yes, FTC/TDF drug levels and hormone levels are not affected



HIV Prevention

- iBrEATHe study: compared TFV-DP concentrations between transgender women taking estradiol (n = 24) and a control group of cisgender men (n=15)
- All taking PrEP under with directly observed therapy




TFV-DP concentrations during PrEP, TGW vs CGM Estradiol concentrations before and during PrEP, TGW



Deutsch MB, et al. *Lancet HIV*. 2015; 2(12):e512-e519; 109(1):e1-e8; Grant RM, et al. *Clin Infect Dis*. 2020;ciaa1160. Image courtesy Prime Education



- Transwomen: FTC/TDF or FTC/TAF
- Transmen: FTC/TDF






HIV Care

- Most drugs don't interact with genderaffirming hormones
- Require closer hormone monitoring
- Drugs most like to interact:
- Etravirine
- Nevirapine
- Elvitegravir (+/- cobicistat or ritonavir)
- Protease inhibitors (+ cobicistat or ritonavir)





https://clinicalinfo.hiv.gov/sites/default/files/guidelines/archive/AdultandAdolescentGL_2021_08_16.pdf.



Southeast

Homework

- 1. Ali is a 35 yo transgender women who would like to start feminizing hormones. She has no family history of clotting disorders and no personal history of blood clots. She smokes a few cigarettes each week. She has no other medical history. She is sexually active only with her girlfriend a one cisgender women. How would you counsel Ali? Would you start hormones? What hormones would you start?
- 2. Robert is a 25 yo transgender man who would like to start masculinizing hormones. He has been living as a man for the past year and has known he was a man for as long as he remembers. He has no past medical history. He has no family history of cancer or cardiovascular disease. He is sexually active with one cis gender female partner. He has no sex that could result in pregnancy. He has no desire for future fertility. How would you counsel Robert? Would you start hormones? What hormones would you start?



A PROGRAM OF THE FENWAY INSTITUTE	What We Offer 🗸 About Us 🗸 My Learning 🗸 🍳
We Are The National LGBTQIA+ Health Education Center	What's New?
We provide educational programs, resources, and consultation to health care organizations with the goal of optimizing quality, cost-effective health care for lesbian, gay, bisexual, transgender, queer, intersex, asexual, and all sexual and gender minority (LGBTQIA+) people.	Housing and Older LGBTQIA+ Adults – Part 1 I Webinar 16 March, 2021 For this webinar series, The National LGBTQIA+

UCSF Transgender Care

For Patients - For Providers - Our Team - Schedule an Appointment

For Providers » Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People

Welcome	Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People
Place a Referral	Care of Transgender and Gender Nonomary reopie
e-Consults (Internal to UCSF Medical Center only)	Publication Date: June 17, 2016



Online Resources



Practice Cultural <u>Humility</u>



"Proposes change through a lifelong process of learning, including self-examination and refinement of one's own awareness, knowledge, behavior and attitudes on the interplay of power, privilege and social contexts"

How can you make your practice/health system more inclusive to transgender patients?

A GT (C) And Structure & Garcia, J. (1998) Cultural humility versus cultural competence: A critical distinction in defining physician-training outcomes in multicultural education. Journal of Colored System System 2019 and Underserved, 9(2), 117.

Thank you and Questions! ryan.nall@medicine.ufl.edu



AETC Program National Centers and HIV Curriculum

- National Coordinating Resource Center serves as the central web based repository for AETC Program training and capacity building resources; its website includes a free virtual library with training and technical assistance materials, a program directory, and a calendar of trainings and other events. Learn more: <u>https://aidsetc.org/</u>
- National Clinical Consultation Center provides free, peer-to-peer, expert advice for health professionals on HIV prevention, care, and treatment and related topics. Learn more: <u>https://nccc/ucsf.edu</u>
- National HIV Curriculum provides ongoing, up –to-date HIV training and information for health professionals through a free, web –based curriculum; also provides free CME credits, CNE contact hours, CE contact hours, and maintenance of certification credits. Learn more: <u>www.hiv.uw.edu</u>

